IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026 REHOVOT, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) ( ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support (PS). IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, was previously ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The ...

GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST. The audio link for Emergent’s session may be accessed here and will be live for up to 30 days. The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergen ...

公司近期动态 - 公司将于2026年1月14日太平洋时间上午9点 在第44届摩根大通医疗健康大会上进行演讲 [1] 公司信息获取渠道 - 演讲将通过公司官网投资者与媒体板块的活动与演示页面进行网络直播 [2] - 网络直播录像将在公司官网保留约30天 [2] 公司业务与战略定位 - 公司是一家领先的临床阶段基因编辑公司 致力于利用CRISPR技术革新医学 [1][3] - 公司自成立以来 专注于利用基因编辑技术开发新颖的、首创的疗法 以解决未满足的重大医疗需求并推进患者治疗模式 [3] - 公司旨在通过其深厚的科学、技术和临床开发经验 为新型药物类别设定标准 [3] - 为充分发挥基因编辑潜力 公司正通过新颖的编辑和递送技术持续扩展其CRISPR平台的能力 [3]

公司近期动态 - 公司将于2026年1月14日太平洋时间上午9点 在第44届摩根大通医疗健康年会上进行演讲 [1] 公司信息获取渠道 - 演讲将通过公司官网投资者与媒体板块的活动与演讲页面进行网络直播 [2] - 网络直播的回放将在公司官网上保留大约30天 [2] 公司业务与战略 - 公司是一家领先的临床阶段基因编辑公司 专注于利用基于CRISPR的疗法革新医学 [1][3] - 公司自成立以来 专注于利用基因编辑技术开发新颖的、首创的疗法 以解决重要的未满足医疗需求并推进患者的治疗模式 [3] - 公司正通过新颖的编辑和递送技术 持续扩展其基于CRISPR平台的潜力 [3] - 公司深厚的科学、技术和临床开发经验 正在帮助设定新一类药物的标准 [3]

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D. ...

WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media se ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients ...

丽珠集团（000513）(000513.SZ)公告，公司控股子公司珠海市丽珠单抗生物技术有限公司("丽珠单抗") 与北京鑫康合生物医药科技有限公司联合开发的产品莱康奇塔单抗注射液于2025年12月26日被国家药品 监督管理局药品审评中心纳入拟优先审评品种公示名单;现公示期满后，根据国家药品监督管理局药品 审评中心网站信息公开显示，已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。 ...